Miller, Katelyn D. http://orcid.org/0000-0003-3334-6289
O’Connor, Seamus
Pniewski, Katherine A.
Kannan, Toshitha http://orcid.org/0009-0007-7775-6585
Acosta, Reyes
Mirji, Gauri
Papp, Sara
Hulse, Michael
Mukha, Dzmitry http://orcid.org/0000-0003-3027-6270
Hlavaty, Sabina I. http://orcid.org/0000-0001-6863-1819
Salcido, Kelsey N.
Bertolazzi, Fabrizio http://orcid.org/0000-0003-2121-1272
Srikanth, Yellamelli V. V.
Zhao, Steven http://orcid.org/0000-0002-8102-8368
Wellen, Kathryn E. http://orcid.org/0000-0002-2281-0042
Shinde, Rahul S. http://orcid.org/0000-0001-8767-5032
Claiborne, Daniel T.
Kossenkov, Andrew
Salvino, Joseph M. http://orcid.org/0000-0002-2184-5980
Schug, Zachary T. http://orcid.org/0000-0003-4197-8227
Funding for this research was provided by:
Susan G. Komen (CCR19608782)
V Foundation for Cancer Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute (DP2 CA249950, P01 CA114046, T32 CA009171, CA259240)
American Cancer Society (PF-20-1225-01-CCG)
Article History
Received: 5 April 2022
Accepted: 17 August 2023
First Online: 18 September 2023
Competing interests
: J.M.S. and Z.T.S. are scientific co-founders and consultants for Syndeavor Therapeutics. The remaining authors declare no competing interests.